18 results about "Immunoactivators" patented technology

Immunotherapeutic Monoclonal Antibody Complexes or Conjugates (IMAC) comprising readily accessible antibodies designed and approved for clinical use are provided using a one-step method that combines killing of existing cancer cells in parallel with induction of long-lasting anti-cancer vaccination. Methods for their use, alone or in combination with cancer killer cells including intentionally mismatched donor T cells, NK cells concomitantly with additional anti-cancer or immune activating agents, or activation of patient's own immune system for personalized treatment of cancer and elimination of undesirable non-malignant cells are also provided. In addition, treatment method based on IMAC can be applied for in vivo vaccination against cancer using an existing malignant lesion as internal anti-cancer vaccine by engagement of patients antigen presenting cells for induction of long-lasting anti-cancer vaccination in situ against residual or recurrent disease.

The invention relates to the field of chemical synthesis of nucleoside and oligonucleotide and the field of innate immunity, and discloses cyclic dinucleotide 2 ', 3'-cG4 '-MeAMP, a preparation method and application of the cyclic dinucleotide 2', 3 '-cG4'-MeAMP in preparation of innate immunity activators, the chemical structural formula of the cyclic dinucleotide 2 ', 3'-cG4 '-MeAMP is shown in the specification, and compared with natural cyclic dinucleotide 2', 3 '-cGAMP, the cyclic dinucleotide 2', 3 '-cG4'-MeAMP has the structural formula shown in the specification. The 3 '-cG4'-MeAMP has higher serum stability, has a remarkably enhanced innate immune activation effect on human cells carrying an inactivated STING-R232H mutant, and shows a potential treatment value in STING function defect related diseases.

The invention provides an IgG (immunoglobulin G) binding type immune activator protein as well as a preparation method and application thereof, and belongs to the technical field of medicines. It is found for the first time that after three Fab binding peptides CFab and N215 are fused, the N215 can be endowed with the IgG antibody binding capacity, the obtained fusion protein N215-CFab3 and the IgG antibody can form a stable compound, and the compound retains the functions of the N215 and the antibody, can mediate binding of the N215 to target cells, remarkably prolongs the half-life period of the N215, promotes proliferation of T and NK cells, and has the advantages of being capable of achieving the purpose of improving the immunogenicity of the N215 and improving the immunogenicity of the N215. The remarkably enhanced in-vivo anti-tumor effect is exerted. A compound formed by the fusion protein N215-CFab3 and an IgG antibody can be used as an immune activator, and has a wide application prospect in immunotherapy of diseases such as tumors and infection.

The application discloses an application of ergothioneine in antiviral in the field of biotechnology. The ergothioneine plays an immune activation role at least by activating TLR4 and downstream NF-kappa B signal pathways. The ergothioneine is used for preparing an immunomodulator or an antiviral drug, can effectively activate immune cells and enhance antiviral capacity, to a certain extent, overcomes defects of traditional technologies, reduces problems of large side effects of current TLR4 agonists, and provides a new idea for developing a novel immunomodulator and an antiviral treatment strategy.

The invention relates to genetic engineering and medicine, in particular to application of rhodinine in preparation of T cell activation drugs. The invention provides an application of rhodinine in preparation of a medicine of a T cell activator. The method comprises the following steps: detecting the GFP fluorescence intensity of the NFAT-GFP report Jurkat T by using an InucyteSX5 high-throughput living cell analyzer, screening an immune activator from a natural compound library, detecting the NFAT-GFP report Jurkat T by using the Inucyte high-throughput living cell analyzer, and carrying out secondary screening, so as to obtain the rose tree alkali capable of effectively activating T cells. According to the present invention, the T cell activation performance of the rhodinine is verified through the research on the activation of the NFAT transcription factor by the rhodinine and the research on the influence of the rhodinine on the expression of the CD25 on the surface of the NFAT-GFP report Jurkat T cell;

Immunotherapeutic Monoclonal Antibody Complexes or Conjugates (IMAC) comprising readily accessible antibodies designed and approved for clinical use are provided using a one-step method that combines killing of existing cancer cells in parallel with induction of long-lasting anti-cancer vaccination. Methods for their use, alone or in combination with cancer killer cells including intentionally mismatched donor T cells, NK cells concomitantly with additional anti-cancer or immune activating agents, or activation of patient's own immune system for personalized treatment of cancer and elimination of undesirable non-malignant cells are also provided. In addition, treatment method based on IMAC can be applied for in vivo vaccination against cancer using an existing malignant lesion as internal anti-cancer vaccine by engagement of patient's antigen presenting cells for induction of long-lasting anti-cancer vaccination in situ against residual or recurrent disease.

The present invention provides a hyperthermia-induced gut microbiome- mediated modulation of the host immune system for the treatment of gastric / gastric MALT / Duodenum cancer; the said system uses a wild type / non-pathogenic / attenuated strain coated with iron oxide nanoparticles to specifically target the cancerous tissue by applying an external field around the gastric tissue the said iron oxide generates heat on bacteria surface and causes lysis of bacteria in the tumor microenvironment; the lysis of bacteria triggers various potent immune activator and cytokines to activate antigen-presenting cells including lymphocytes and macrophages; the said antigen presenting cell further, eliminates cancer cell from the gut microenvironment and eventually clean tumor microenvironment. Additionally, the activated lymphocytes will be antigenic memory against bacterial particles and cancer tissues. Furthermore, the said treatment system does not involve the use of any chemotherapeutic drug or radiation treatment and, thus, precludes undesirable side effects of chemotherapy as well as minimizes toxicity.

The invention relates to the technical field of plant protection, in particular to a cryphonectria parasitica prevention and control method using validamycin as an immune activator to be mixed with biocontrol bacterium fermentation filtrate. According to the technical scheme, the method comprises the following steps: preparing a culture medium by using different concentrations of validamycin solutions and bacillus velezensis B268 fermentation filtrate diluted by different multiples, transferring the culture medium to a bacterial cake for culture, performing indoor toxicity determination, spraying three treatment groups according to a result obtained in the step 2 as a spraying concentration, performing living body inoculation after spraying a medicament for 1 day, and performing secondary inoculation after the medicament is sprayed for 1 day. After inoculation, collecting each group of leaves for defensive enzyme activity determination and MDA content determination, and collecting part of samples for transcriptome sequencing. The validamycin and the bacillus velezensis B268 fermentation filtrate are mixed to play a synergistic effect, so that the disease prevention effect is improved.

This invention relates to the fields of chemical synthesis of nucleosides and oligonucleotides and innate immunity. The invention discloses a cyclic dinucleotide 2′,3′-cG 4′‑Me AMP, its preparation method, and its application in the preparation of innate immune activators, wherein the cyclic dinucleotide 2′,3′-cG 4′‑Me The chemical structure of AMP is shown below. Compared with the natural cyclic dinucleotide 2′,3′-cGAMP, 2′,3′-cGAMP has different chemical structures. 4′‑Me AMP exhibits higher serum stability and significantly enhances innate immune activation in human cells carrying the inactivated STING-R232H mutant, demonstrating its potential therapeutic value in diseases related to STING dysfunction.

The invention relates to the field of microorganisms, in particular to an application of a metagen of fermented lactobacillus mucus in preparation of an immune activator, the fermented lactobacillus mucus is Limosilicobacterium fermentum B44, and the metagen is a substance prepared by the following method: centrifugally collecting the fermented lactobacillus mucus in fermented lactobacillus mucus fermentation liquor, washing and then resuspending, and drying to obtain the immune activator. And inactivating the thalli, cooling, centrifuging, retaining the precipitate, and freeze-drying to obtain the metabiotics. The immune activator is a macrophage activator, the food safety can be guaranteed, the preparation method is simple and convenient, the applicability is high, the immune activator has very good immune activation ability, has the characteristics of inactivity and stability, can be widely applied to foods, dietary supplements, fermented and non-fermented milk products and the like, and has very good product processability.

The invention belongs to the technical field of medicines, and particularly relates to ROS (reactive oxygen species) double-response nanoparticles for co-delivery of metabolic inhibitors and immune activators as well as a preparation method and application of the ROS double-response nanoparticles. The nanoparticles comprise a phenylboronic acid ester modified polymer which responds to ROS cracking, a ferrocene modified polymer which responds to ROS catalytic Fenton reaction, S-Gboxin which inhibits mitochondrial ATP synthesis, and a TGF-beta inhibitor Galunissertib which regulates immunity. The nanoparticles are targeted to Glut1 through DHA to mediate tumor targeting, and after entering tumor tissues and incorporating cells, the nanoparticles respond to ROS phenylboronic acid ester splitting decomposition, and drug release is accelerated; and under the catalysis of ferrocene, the common ROS in the tumor cells is converted into the superoxide compound with higher oxidation capacity. The released S-Gboxin is combined with the inner membrane of mitochondria, so that the membrane potential is reduced, and the tumor energy supply is inhibited. Similarly, the Galunissertib down regulates the tumor microenvironment TGF-beta, inhibits the expression of proteins pSMAD2 / 3 and TSP-1, and remodels the immunosuppressive microenvironment.

The invention relates to genetic engineering and medicine, in particular to application of rhodinine in preparation of T cell activation drugs. The invention provides an application of rhodinine in preparation of a medicine of a T cell activator. The method comprises the following steps: detecting the GFP fluorescence intensity of the NFAT-GFP report Jurkat T by using an InucyteSX5 high-throughput living cell analyzer, screening an immune activator from a natural compound library, detecting the NFAT-GFP report Jurkat T by using the Inucyte high-throughput living cell analyzer, and carrying out secondary screening, so as to obtain the rose tree alkali capable of effectively activating T cells. According to the present invention, the T cell activation performance of the rhodinine is verified through the research on the activation of the NFAT transcription factor by the rhodinine and the research on the influence of the rhodinine on the expression of the CD25 on the surface of the NFAT-GFP report Jurkat T cell;

The invention provides preparation and application of a responsive nano assembly capable of overcoming chemotherapy resistance and improving an immunotherapy effect at the same time. A nano drug carrier is prepared from chitosan oligosaccharide, carboxyl azobenzene, PEG-modified lipid, a chemotherapy sensitizer, a chemotherapy drug and an immune activator. The invention also provides application of the nano-drug in preparation of drugs for treating tumors, improving drug-resistant tumor sensitivity, treating tumors and improving drug-resistant tumor sensitivity for synergistic treatment. According to the invention, a chemotherapeutic drug, an active molecule for reducing the resistance of the chemotherapeutic drug and an immune activation drug are ingeniously integrated into the nano-carrier, and the prepared nano-carrier ensures stable blood circulation and better permeation into a deep tumor part due to slight negative charges on the surface and a smaller particle size; the tumor microenvironment response release ensures the effective release of the chemotherapy drug and the chemotherapy sensitizer in the tumor microenvironment, and the chemotherapy drug resistance of the tumor is reduced through the chemotherapy sensitizer while the tumor chemotherapy is realized.

The application belongs to the technical field of tumor vaccines, and more particularly relates to a tumor personalized vaccine with bacteria as a carrier and a preparation method thereof.The tumor personalized vaccine comprises engineered positive charge bacteria, training immune activators loaded on the engineered positive charge bacteria, and tumor antigens electrostatically adsorbed and adhered to the surface of the engineered positive charge bacteria.By loading the training immune activators on the engineered positive charge bacteria and electrostatically adsorbing the tumor personalized antigens, experiments prove that the tumor personalized vaccine can avoid immune tolerance, improve the retention time of the antigens at an injection site, enhance the recruitment of DCs and monocytes / macrophages at a vaccination site, enhance the uptake and antigen presentation of immune cells, significantly enhance the activation reaction of tumor-specific T cells, weaken the tumor immunosuppressive microenvironment, has an obvious tumor inhibition effect, and realizes precise postoperative treatment for different tumor patients.

The invention belongs to the technical field of preparation of immune activators, and particularly relates to a preparation method of an autoimmune activator. The invention provides a preparation method of an autoimmune activator, which comprises the following steps: separating an albuginea layer from peripheral blood, then respectively preparing an autoimmune exosome and an autovariant cell immune antigen through the steps of resuspension counting, water bath heating, programmed cooling, unfreezing centrifugation and the like, and mixing, freezing and drying to obtain the autoimmune activator. The technical scheme is simple and convenient, the obtained autoimmune activator is high in activity, and after subcutaneous injection, the autoimmune activator can effectively activate subcutaneous Langerhans cells, dendritic cells and the like, enhance the recognition ability of DC cells on antigens, induce Langerhans cells / DC cells to activate Th cells, enhance the effect of effector T cells and remove in-vivo variant cells, so that the autoimmune activator has a good immunogenicity. Therefore, autoimmune diseases or other health problems with immune imbalance states are improved, and the composition is safe and free of side effects.

Disclosed herein are compositions comprising immune-activating agents that bind the tumor cell surface in the absence of a tumor-targeting protein component. Described herein are methods and compositions for targeting a TLR or STING agonist to tumor cells and / or cells in the tumor microenvironment. It is hypothesized that the metabolic stress of tumor growth also produces an excess of unpaired cysteines on cell surface proteins relative to the rest of the body. Therefore, this chemistry can be used with compounds that would preferentially target unpaired cysteines on cell surface proteins.

The invention discloses an exosome-coated spherical ICG photoimmune activator CND-ICG at Exo as well as a preparation method and application thereof, and belongs to the technical field of nano biological medicines. The photoimmune activator is prepared by forming a CND-ICG compound from a carbon dot material CND and indocyanine green ICG through an esterification reaction and then wrapping tumor cell exosomes TDEs through an ultrasonic method. Through covalent coupling of CND and ICG, the defects that free ICG is poor in light stability, low in water solubility and rapid in-vivo elimination are overcome; by combining the tumor targeting and immune activation capability of TDEs, the photoimmune activator is efficiently enriched at the tumor site of triple negative breast cancer TNBC, the synergistic effect of photothermal tumor killing and immune activation can be achieved under laser irradiation, and meanwhile, the near-infrared imaging function is achieved. The activator is high in tumor cell killing rate and good in biological safety, and a new technical scheme is provided for precise diagnosis and treatment integration of TNBC.

Dislcosed is an immunoactivator that is capable of enhancing induction of both humoral immunity and cellular immunity and contains an active ingredient derived from cell walls (derived from a natural product); a vaccine adjuvant; and a method for inducing immunity including administering the immunoactivator. Theimmunoactivator contains, as an active ingredient, particles having a maximum diameter within a range of 1 to 800 nm, wherein the particles comprise cell-wall-derived polysaccharides.